Previous 10 | Next 10 |
2024-03-28 13:11:15 ET More on Xeris Pharmaceuticals Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript Xeris Biopharma: Speculative Buy, Size Your Position Accordingly Xeris Biopharma Holdings Stock Is A Hold With Robust Performance Into 2024 Xeris Phar...
2024-03-27 16:50:31 ET Gainers: Athira Pharma ( ATHA ) +5% . ContextLogic ( WISH ) +5% . Angi ( ANGI ) +4% . Xeris Biopharma Holdings ( XERS ) +4% . Inozyme Pharma ( INZY ) +3% . Losers: MillerKnoll ( ...
2024-03-06 12:52:43 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Xeris Biopharma Holdings (NASDAQ: XERS ) just reported results for the fourth quarter of 2023. Xeris Biopharma Holdings reported earnings per share of -10 cents. This met ...
2024-03-06 12:50:02 ET Gainers: Aptorum Group Ltd ( APM ) +736% . BiomX ( PHGE ) +144% . Trxade Health ( MEDS ) +87% . New Horizon Aircraft Ltd ( HOVR ) +69% . Rail Vision Ltd ( RVSN ) +62% . Airship AI Holdings ( AISP ) ...
2024-03-06 12:43:15 ET Xeris Biopharma Holdings Inc. (XERS) Q4 2023 Earnings Conference Call March 6, 2024 8:30 am ET Company Participants Paul Edick - Chairman, Chief Executive Officer Steve Pieper - Chief Financial Officer Allison Wey - Senior Vice President, I...
2024-03-06 08:24:28 ET More on Pre-market losers & stocks. Datasea jumps 23% as subsidiary enters a potential $30M sale agreement Seeking Alpha’s Quant Rating on BeyondSpring Historical earnings data for BeyondSpring Financial information for Beyon...
2024-03-06 07:03:17 ET More on Xeris Pharmaceuticals Xeris Biopharma: Speculative Buy, Size Your Position Accordingly Xeris Biopharma Holdings Stock Is A Hold With Robust Performance Into 2024 Xeris Pharmaceuticals Q4 2023 Earnings Preview Amgen in pact with ...
Achieved Total Revenue of over $44M in the fourth quarter – a 34% increase from same period prior year and generated approximately $164M for the full year 2023, a 49% increase versus prior year Ended 2023 with over $72M in cash, cash equivalents, and short-term investments achievin...
Improves cost of capital Increases committed capital to a total facility size of $215M Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products acros...
Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the C...
John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track reco...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2024, the Compensation Committee of Xeris’ Boar...